Previous 10 | Next 10 |
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer PR Newswire DALLAS , Aug. 16, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinica...
CohBar (NASDAQ:CWBR) +62% on Q2 earnings Good Times Restaurant (NASDAQ:GTIM) +32% on Q3 earnings Upstart Holdings (NASDAQ:UPST) +22% on Q2 earnings Mogo (NASDAQ:MOGO) +20% on Q2 earnings fuboTV (NYSE:FUBO) +16% on Q2 earnings Lantern Pharma (N...
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer PR Newswire DALLAS , Aug. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprieta...
Lantern Pharma Inc. (LTRN) Q2 2021 Earnings Conference Call July 29, 2021 04:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - CFO Kishor Bhatia - CSO Conference Call Participants Kyle Bauser - Colliers Securities John Vandermosten - Zacks SCR Presentation Operat...
The following slide deck was published by Lantern Pharma Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Lantern Pharma Inc. 2021 Q2 - Results - Earnings Call Presentation
Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights - Obtained positive preclinical data in pancreatic cancer showing a significant reduction, averaging 93%, in tumor volume in in-vivo animal models from research collaboration with Fox Chase C...
Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer a...
Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET PR Newswire DALLAS , July 22, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company ...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Lantern Pharma Surged 10% Following Positive Cancer Collaboration Data ” Lantern Pharma (NASDAQ: LTRN) climbed over 10% in early morning trading after ...
Vertigo3d/E+ via Getty Images Space flights and earnings reports dominated market coverage on Tuesday. Amazon (AMZN) founder Jeff Bezos took his first trip past the outer atmosphere. Meanwhile, a host of companies released their quarterly results. Virgin Galactic (SPCE) took a dip in Tuesday'...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...